Cordlife Group (SG:P8A) has released an update.
Cordlife Group Limited has ceased its hematopoietic stem cell services related to peripheral blood and has no plans to resume them in the near future, as per their latest announcement. The Company also stated that this cessation will not impact its ongoing cord blood banking operations, which continue under controlled conditions. The Singapore Ministry of Health has noted that any future applications to resume these services would be contingent on Cordlife’s rectification of prior non-compliance issues identified in regulatory inspections.
For further insights into SG:P8A stock, check out TipRanks’ Stock Analysis page.
